27 July 2021 in RSC Medicinal Chemistry
Despite the important roles played by protein–protein interactions (PPIs) in disease, they have been long considered as ‘undruggable’. However, recent advances have suggested that PPIs are druggable but may not follow conventional rules of ‘drug ability’. Here we explore which physicochemical parameters are essential for a PPI modulator to be a clinical drug by analysing the physicochemical properties of small-molecule PPI modulators in the market, in clinical trials, and published. Our analysis reveals that those compounds currently on the market have a larger range of values for most of the physicochemical parameters, whereas those in clinical trials fit much more stringently to standard drug-like parameters. This observation was particularly true for molecular weight, clog P and topological polar surface area, where aside from a few outliers, most of the compounds in clinical trials fit within standard drug-like parameters. This implies that the newer PPI modulators are more drug-like than those currently on the market, suggesting that designing new PPI-specific screening libraries should remain within standard drug-like parameters in order to obtain a clinical candidate. Taken together, our analysis has important implications for designing future drug discovery campaigns aimed at targeting PPIs.
24 June 2022 in Blood Advances
Telomere biology disorders (TBDs) are a spectrum of multisystem inherited disorders characterized by bone marrow failure, resulting from mutations in the genes encoding telomerase or other proteins involved in maintaining telomere length and integrity. Pathogenicity of variants in these genes can be hard to evaluate, because TBD mutations show highly variable penetrance and genetic anticipation related to inheritance of shorter telomeres with each generation. Thus, detailed functional analysis of newly identified variants is often essential. Herein, we describe a patient with compound heterozygous variants in the TERT gene, which encodes the catalytic subunit of telomerase, hTERT. This patient had the extremely severe Hoyeraal-Hreidarsson form of TBD, although his heterozygous parents were clinically unaffected. Molecular dynamic modeling and detailed biochemical analyses demonstrate that one allele (L557P) affects association of hTERT with its cognate RNA component hTR, whereas the other (K1050E) affects the binding of telomerase to its DNA substrate and enzyme processivity. Unexpectedly, the data demonstrate a functional interaction between the proteins encoded by the two alleles, with wild-type hTERT rescuing the effect of K1050E on processivity, whereas L557P hTERT does not. These data contribute to the mechanistic understanding of telomerase, indicating that RNA binding in one hTERT molecule affects the processivity of telomere addition by the other molecule. This work emphasizes the importance of functional characterization of TERT variants to reach a definitive molecular diagnosis for patients with TBD, and, in particular, it illustrates the importance of analyzing the effects of compound heterozygous variants in combination, to reveal interallelic effects.
1 July 2019 in Acta Crystallographica Section D Structural Biology
Two commonly encountered bottlenecks in the structure determination of a protein by X-ray crystallography are screening for conditions that give high-quality crystals and, in the case of novel structures, finding derivatization conditions for experimental phasing. In this study, the phasing molecule 5-amino-2,4,6-triiodoisophthalic acid (I3C) was added to a random microseed matrix screen to generate high-quality crystals derivatized with I3C in a single optimization experiment. I3C, often referred to as the magic triangle, contains an aromatic ring scaffold with three bound I atoms. This approach was applied to efficiently phase the structures of hen egg-white lysozyme and the N-terminal domain of the Orf11 protein fromStaphylococcusphage P68 (Orf11 NTD) using SAD phasing. The structure of Orf11 NTD suggests that it may play a role as a virion-associated lysin or endolysin.
28 April 2021 in Acta Crystallographica Section F Structural Biology Communications
1 August 2022 in Proteins: Structure, Function, and Bioinformatics
19 May 2026 in Biotechnology and Bioengineering
Immobilised Metal Affinity Chromatography (IMAC) is widely used to purify his‐tagged recombinant proteins from Escherichia coli . However, endogenous contaminants with histidine clusters, such as GFAT and PDH E1 proteins, are often co‐purified with the target protein. The low background strain LOBSTR‐RIL has been previously engineered with mutated forms of SlyD and ArnA that exhibit reduced binding to Ni 2+ resin. In this study, the LOBSTR‐RIL strain was further modified to produce IMACulate(DE3), where we altered the glmS (encoding GFAT protein) and aceE (encoding PDH E1 protein) genes to reduce surface histidines. Proteins purified from this strain show reduced levels of GFAT contamination. No statistically significant difference was observed in the abundance levels of PDH E1 protein in the BL21(DE3)‐RIL, LOBSTR‐RIL and IMACulate(DE3) strains. The use of IMACulate(DE3) increases the purity of recombinant his‐tagged protein preparations with no additional effort or expense.